摘要
目的:构建以MAGE-1(161-169)为表位的癌症基因疫苗并检测其抗小鼠黑色素瘤效果。方法:构建基因疫苗pcDNA-HSP70-MAGE-1(161-169),并免疫C57BL/6小鼠。最后一次免疫后第2周,接种小鼠黑色素瘤细胞。于肿瘤细胞接种后14 d,处死全部动物,称量肿瘤的重量。采用ELISA法对小鼠血清中抗MAGE-1-IgG类抗体及小鼠原代脾淋巴细胞IFNγ-释放水平进行检测。结果:pcDNA-HSP70-MAGE-1(161-169)表位基因疫苗能够成功地诱发机体产生抗MAGE-1的特异性抗体,并能在体内起到抗小鼠黑色素瘤作用,抑瘤率为40.7%。同时还能提高约3.05倍的小鼠原代脾淋巴细胞IFNγ-释放量。结论:pcDNA-HSP70-MAGE-1(161-169)有望成为有效的抗小鼠黑色素瘤基因疫苗。
AIM： Construction of MAGE-1（161-169） DNA vaccine and evaluated its anti-melanoma effects in mouse. METHODS： A DNA vaccine pcDNA3. 1- HSP70-MAGE-1（161-169） has been constructed and used to immunize mice 3 times at 2-weekly intervals. Two weeks after the last immunization, tumor challenge experiments were performed by using B16F10 melanoma cell. After 14 d of challenge experiments, all mice were sacrificed and tumors were weighted. The specific anti-MAGE-1 IgG antibodies and the IFN-7 released by mouse primary splenocytes were detected by ELISA methods. RESULTS： The specific anti-MAGE-1 antibodies were detected in the serum of the mice immunized with pcDNA3. 1-HSP70-MAGE-1（161-169） DNA vaccine. It showed that B16F10 melanoma growth in mice of DNA vaccine group was obviously suppressed compared with that in saline control group , with tumor inhibitory rate of 40.7%. The IFN-7 released by mouse primary splenocytes in mice of HSP70-MAGE- 1（161-169） DNA vaccine group was 3.05 times of that in saline control group. CONCLUSION： pcDNA3. 1- HSP70-MAGE-1（161-169） may be an effective DNA vaccine for the treatment of MAGE-1 dependent tumors.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2009年第7期785-789,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
江苏省药效研究和评价服务中心资助项目(BM2005103)
